Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cel-Sci hopes “True Cold” gets warm reception in biologics sector
By Garet6h Macdonald
03-Sep-2009
http://www.outsourcing-pharma.com/Product-Categories/Fill-finish-packaging/Cel-Sci-hopes-True-Cold-gets-warm-reception-in-biologics-sector
Unilife Proposes Redomiciliation Of Unilife Group
Published:01-September-2009
By Staff Reporter
http://www.pharmaceutical-business-review.com/news/unilife_proposes_redomiciliation_of_unilife_group_090901
Unilife US to become the ultimate parent company of the Unilife group
Unilife Australia has entered into a Merger Implementation Agreement with Unilife Corporation (Unilife US), a wholly owned subsidiary of Unilife Australia. The purpose of the Merger Implementation Agreement is to facilitate the proposed redomiciliation of the Unilife group to the US.
The Proposed Transaction will be implemented by the establishment of a new corporate structure under which Unilife US, a company incorporated in Delaware, US, will become the ultimate parent company of the Unilife group (Group). As a result, shareholders and optionholders of Unilife Australia will exchange their existing interests in Unilife Australia for equivalent interests in Unilife US.
The Group's business, operations, management and employees will not materially change as a result of the Proposed Transaction. Upon implementation of the Proposed Transaction, the Board of Unilife US will be restructured to reflect the Group's domicile in the US.
The Proposed Transaction is subject to approval by the Australian Federal Court as well as approval of Unilife Australia Security Holders
Sequenom shares up on Down Syndrome test chatter
http://biomedreports.com/articles/most-popular/7415-sqnm-shares-flying-on-down-syndrome-test-chatter.html
31.08.2009 19:09
http://www.finanznachrichten.de/nachrichten-2009-08/14827018-sequenom-shares-up-on-down-syndrome-test-chatter-020.htm
By Shailesh Kuber and Doris Frankel
BANGALORE/CHICAGO, Aug 31 (Reuters) - Shares of Sequenom Inc rose as much as 17 percent amid speculation that the company's prenatal Down Syndrome test may yield favorable results.
'There is chatter about possible news regarding favorable results from a medical study that might benefit the company,' said Frederic Ruffy, options strategist at Web information site WhatsTrading.com.
'Traders appear to be looking for more upside in shares and are buying September $6 and $7.50 calls,' he added.
In April, the company delayed the launch of the SEQureDx test, citing mishandling of research and development test data and results by employees, and had initiated an independent investigation into the matter.
In morning trade, about 25,000 call options traded in the name, more than two times its normal daily volume and nearly 11 times the number of its put options, according to option analytics firm Trade Alert.
Investors often turn to equity call options -- granting the right to buy the company's shares at a fixed price within a specified time period -- to speculate on potential share price appreciation.
An equity put option conveys the right to sell the stock at a given price and time.
Auriga USA analyst Raj Mehra said there were rumors in the market about positive data from the study on the company's Down Syndrome test.
Shares of the company were up 79 cents at $6.06 in afternoon trade. They rose as much as $6.19 earlier in the session.
(Editing by Maju Samuel) Keywords: SEQUENOM/SHARES
(shailesh.kuber@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: shailesh.kuber.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
! you are wrong :
Files shelf to offer up to $40 million...
NOT
This registration of 40M shares additional...
Going vacation!
(for next 10days... > no time at this moment - ax )
...good idea!
Please if you resend the email send it like "International Investorsgroup want to know..."
Keryx Biopharmaceuticals files shelf
http://www.finanznachrichten.de/nachrichten-2009-08/14813732-brief-keryx-biopharmaceuticals-files-shelf-020.htm
Aug 28 (Reuters) - Keryx Biopharmaceuticals Inc:
* Files shelf to offer up to $40 million in stock and warrants - SEC filing
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
Copyright Thomson Reuters 2009. All rights reserved.
*******************************************************************
SEC-FILING (FORM S-3):
http://www.sec.gov/Archives/edgar/data/1114220/000114420409046290/v159057_s-3.htm
$40,000,000
Keryx Biopharmaceuticals, Inc.
Common Stock
Warrants
We may offer and sell an indeterminate number of shares of our common stock and/or warrants from time to time under this prospectus. You should read this prospectus and any supplement carefully before you invest.
We may offer our common stock and/or warrants in one or more offerings in amounts, at prices, and on terms determined at the time of the offering. We may sell our common stock and warrants through agents we select or through underwriters and dealers we select. If we use agents, underwriters or dealers, we will name them and describe their compensation in a prospectus supplement.
This prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before you invest in any securities. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement.
Our common stock is traded on the Nasdaq Capital Market under the symbol “KERX.” On August 27, 2009, the per share closing price of our common stock as reported on the Nasdaq Capital Market was $1.39 per share.
As of August 27, 2009, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $62,114,220, which was calculated based on 44,686,489 shares of outstanding common stock held by non-affiliates and on a price per share of $1.39, the closing price of our common stock on August 27, 2009. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding more than one-third of our market value in any 12-month period so long as our market value remains below $75.0 million. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.
DESCRIPTION OF COMMON STOCK
The following summary of the terms of our common stock may not be complete and is subject to, and qualified in its entirety by reference to, the terms and provisions of our certificate of incorporation and our bylaws. You should refer to, and read this summary together with, our certificate of incorporation and bylaws to review all of the terms of our common stock that may be important to you.
Common Stock
Under our certificate of incorporation, we are authorized to issue a total of 95,000,000 shares of common stock, par value $0.001 per share. As of August 27, 2009, we had issued and outstanding 47,838,960 shares of our common stock. There are approximately 61 holders of record. All outstanding shares of our common stock are fully paid and nonassessable. Our common stock is listed on the Nasdaq Capital Market under the symbol "KERX."
Dividends
Holders of our common stock are entitled to participate equally in dividends when our Board of Directors declares dividends on our common stock out of legally available funds. We have never declared or paid any cash dividends on our common stock and do not anticipate paying any such cash dividends in the foreseeable future. Future dividends, if any, will be determined by our Board of Directors and will be based upon our earnings, capital requirements and operating and financial condition, among other factors, at the time any such dividends are considered by our Board of Directors.
Voting Rights
The holders of our common stock are entitled to one vote for each share of common stock held. Generally, the vote of the majority of the shares represented at a meeting of the stockholders and entitled to vote is sufficient for actions that require a vote of the stockholders.
Liquidation and Dissolution
In the event of our liquidation, dissolution, or winding up, voluntarily or involuntarily, holders of our common stock will have the right to a ratable portion of the assets remaining after satisfaction in full of the prior rights of our creditors and of all liabilities.
Other
Holders of our common stock are not entitled to any preemptive or preferential right to purchase or subscribe for shares of capital stock of any class and have no conversion or sinking fund rights.
Transfer Agent
American Stock Transfer and Trust Company serves as the transfer agent and registrar for all of our common stock.
DESCRIPTION OF WARRANTS
We may issue warrants to purchase shares of our common stock. We may issue warrants independently or together with other securities. Warrants sold with other securities may be attached to or separate from the other securities. We will issue warrants under one or more warrant agreements between us and a warrant agent that we will name in the prospectus supplement.
Keryx Biopharmaceuticals files shelf
http://www.finanznachrichten.de/nachrichten-2009-08/14813732-brief-keryx-biopharmaceuticals-files-shelf-020.htm
Aug 28 (Reuters) - Keryx Biopharmaceuticals Inc:
* Files shelf to offer up to $40 million in stock and warrants - SEC filing
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
Copyright Thomson Reuters 2009. All rights reserved.
*******************************************************************
SEC-FILING (FORM S-3):
http://www.sec.gov/Archives/edgar/data/1114220/000114420409046290/v159057_s-3.htm
$40,000,000
Keryx Biopharmaceuticals, Inc.
Common Stock
Warrants
We may offer and sell an indeterminate number of shares of our common stock and/or warrants from time to time under this prospectus. You should read this prospectus and any supplement carefully before you invest.
We may offer our common stock and/or warrants in one or more offerings in amounts, at prices, and on terms determined at the time of the offering. We may sell our common stock and warrants through agents we select or through underwriters and dealers we select. If we use agents, underwriters or dealers, we will name them and describe their compensation in a prospectus supplement.
This prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before you invest in any securities. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement.
Our common stock is traded on the Nasdaq Capital Market under the symbol “KERX.” On August 27, 2009, the per share closing price of our common stock as reported on the Nasdaq Capital Market was $1.39 per share.
As of August 27, 2009, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $62,114,220, which was calculated based on 44,686,489 shares of outstanding common stock held by non-affiliates and on a price per share of $1.39, the closing price of our common stock on August 27, 2009. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding more than one-third of our market value in any 12-month period so long as our market value remains below $75.0 million. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.
DESCRIPTION OF COMMON STOCK
The following summary of the terms of our common stock may not be complete and is subject to, and qualified in its entirety by reference to, the terms and provisions of our certificate of incorporation and our bylaws. You should refer to, and read this summary together with, our certificate of incorporation and bylaws to review all of the terms of our common stock that may be important to you.
Common Stock
Under our certificate of incorporation, we are authorized to issue a total of 95,000,000 shares of common stock, par value $0.001 per share. As of August 27, 2009, we had issued and outstanding 47,838,960 shares of our common stock. There are approximately 61 holders of record. All outstanding shares of our common stock are fully paid and nonassessable. Our common stock is listed on the Nasdaq Capital Market under the symbol "KERX."
Dividends
Holders of our common stock are entitled to participate equally in dividends when our Board of Directors declares dividends on our common stock out of legally available funds. We have never declared or paid any cash dividends on our common stock and do not anticipate paying any such cash dividends in the foreseeable future. Future dividends, if any, will be determined by our Board of Directors and will be based upon our earnings, capital requirements and operating and financial condition, among other factors, at the time any such dividends are considered by our Board of Directors.
Voting Rights
The holders of our common stock are entitled to one vote for each share of common stock held. Generally, the vote of the majority of the shares represented at a meeting of the stockholders and entitled to vote is sufficient for actions that require a vote of the stockholders.
Liquidation and Dissolution
In the event of our liquidation, dissolution, or winding up, voluntarily or involuntarily, holders of our common stock will have the right to a ratable portion of the assets remaining after satisfaction in full of the prior rights of our creditors and of all liabilities.
Other
Holders of our common stock are not entitled to any preemptive or preferential right to purchase or subscribe for shares of capital stock of any class and have no conversion or sinking fund rights.
Transfer Agent
American Stock Transfer and Trust Company serves as the transfer agent and registrar for all of our common stock.
DESCRIPTION OF WARRANTS
We may issue warrants to purchase shares of our common stock. We may issue warrants independently or together with other securities. Warrants sold with other securities may be attached to or separate from the other securities. We will issue warrants under one or more warrant agreements between us and a warrant agent that we will name in the prospectus supplement.
Delta and Mesa Air lock horns again
Friday, August 28, 2009, 7:43pm EDT |
Modified: Saturday, August 29, 2009, 1:19am
Atlanta Business Chronicle - by J. Scott Trubey Staff Writer
http://www.bizjournals.com/atlanta/stories/2009/08/24/daily100.html?surround=lfn
Delta Air Lines Inc. has filed a new lawsuit in its continued attempt to break a contract with Delta Connection partner Mesa Air Group Inc.
Mesa, parent of Connection carrier Freedom Airlines, said in a Friday regulatory filing that Delta had filed suit in federal court seeking declaratory judgment to terminate the contract based on “material breach by Freedom,” according to Securities and Exchange Commission filing.
Over the past 18 months, Delta has had a series of disputes with other Delta Connection partners, some of which have been resolved.
The suit, filed Aug. 19, is the latest salvo in a contractual battle between Delta and Mesa.
“After months of working in good faith to try to resolve a contractual billing dispute with Mesa, we unfortunately have been left with no choice but to ask a court to resolve Mesa’s refusal to honor its contract pricing guarantees," Delta spokeswoman Kristin Baur said in a e-mail. " We expect Mesa and Freedom to keep their promises to Delta and our customers, and so far, they have refused to do so.”
In April 2008, after Delta tried to buy Mesa out of its contract, and Mesa declined, Delta sent a letter to Mesa terminating the contract saying Mesa’s percentage of flight cancellations exceeded contractual limits, counting so-called coordinated cancellations, according to court documents. Mesa won a preliminary injunction to stop Delta from cutting ties, and the U.S. Court of Appeals for the 11th Circuit affirmed a preliminary injunction last month.
The case is expected to go to trial later this year.
Mesa has said it will be forced into bankruptcy if Delta is allowed to revoke the contract.
Airline analysts have said Delta, especially since its merger last year with Northwest Airlines, has agreements with contract carriers to fly too many regional jets. Regional jets are typically cost effective at oil prices below $50 per barrel.
In the run up of fuel prices in early- to mid- 2008, Delta started exploring its options to reduce its number of contract carriers. Delta tried to terminate contracts with Mesa Air Group and Pinnacle Airlines Inc last year. Delta and ExpressJet Holdings Inc. mutually ended their contract in 2008.
“The alleged material breach relates to Delta's efforts to impose certain cost reductions on Freedom,” Phoenix, Ariz.-based Mesa said in its Friday SEC filing. “Freedom believes that Delta's claims are wholly without merit and are a direct effort by Delta to circumvent the injunction prohibiting Delta from terminating Freedom's Connection Agreement, which was recently upheld by the 11th Circuit Court of Appeals.”
...crazy! -
Twins !??? -
WAMUQ - ...monster #2???
LEHMQ - ...what a monster!
CPST - Aug.27, 2009 Meeting Presentation
http://phx.corporate-ir.net
(edit: LONG now)
Capstone Receives Order for Three C800 Microturbines for Brazilian Wastewater Treatment Plant
GlobeNewswire(Mon, Aug 24)
http://biz.yahoo.com/pz/090824/171874.html?.v=1
Capstone Names New Distributor in Mexico and Immediately Receives Order for Four C30 C1D2 Microturbines for Offshore Platforms in Gulf of Mexico
GlobeNewswire(Wed, Aug 26)
http://biz.yahoo.com/pz/090826/172044.html?.v=1
GNBT - in (again) @ €0.455
Generex Biotechnology Corporation's Synthetic Vaccine Platform Represented At International Swine Flu Conference
Director of Immunobiology At Generex Subsidiary Antigen Express as Featured Panelist Discusses Company's Vaccine Technology
http://www.globenewswire.com/newsroom/news.html?ref=rss&&d=172086
WORCESTER, Mass., Aug. 27, 2009 (GLOBE NEWSWIRE) -- The synthetic vaccine platform technology of Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) was featured last week at the first International Swine Flu Conference in Washington, DC.
Douglas M. Powell, PhD, director of immunobiology at Antigen Express, a wholly owned subsidiary of Generex, was a featured panelist in an August 20 discussion that addressed best practices to prepare for the approaching flu season and respond to the pandemic threat posed by the H1N1 virus. The complete panel is archived at C-SPAN.org; Powell's segment begins at 1:03:55: http://www.c-span.org/Watch/Media/2009/08/20/HP/A/22309/International+Swine+Flu+Conference+Day+2.aspx.
Powell explained the advantages of dealing with a pandemic virus by developing next-generation vaccines, such as Generex's synthetic platform, which can be mass-produced using existing technology, more quickly and at lower cost than egg-based vaccines. Powell noted that this process could help prevent infection and/or limit the severity of H1N1 in humans.
Traditional egg-based vaccines take months to develop and rely on live virus, which always carries the risk of infecting rather than inoculating. Generex's proprietary synthetic vaccine platform does not use live virus, but instead arranges peptides to create a "snapshot" of the virus that activates the body's T-cells to fight off the foreign invader, completely eliminating any risk of infection.
Generex's vaccine platform is already in various stage clinical trials for avian flu, as well as prostate, breast and ovarian cancers, melanomas, SARS and HIV/AIDS.
In addition to the company's vaccine platform technology, Generex has developed a range of products based on their proprietary RapidMist(TM) platform technology for drug delivery through the inner lining of the mouth, ensuring that there is no deposit in the lungs. The company's flagship product, Generex Oral-lyn(TM) is an oral insulin spray product for the treatment of Type-1 and Type-2 diabetes, available to patients in certain overseas markets and in Phase III global clinical trials. Generex has also developed and markets a variety of over-the-counter products.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: American Capital Ventures, Inc.
Investor Relations Contact:
Howard Gostfrand
1-877-918-0774
Beckerman Public Relations
Media Contact:
Angelene Taccini
201-465-8024
NexMed Submits Compliance Plan to Nasdaq
Date : 08/27/2009 @ 10:00AM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1251386750&article=39225222&symbol=N^NEXM
IMMU - Chart(update) & News-update
27.08.2009 17:01
UPDATE 3-Immunomedics soars as lupus drug shows promise
http://www.finanznachrichten.de/nachrichten-2009-08/14800075-update-3-immunomedics-soars-as-lupus-drug-shows-promise-020.htm
By Ben Hirschler and Anne Jolis
LONDON/BRUSSELS, Aug 27 (Reuters) - Immunomedics became the second biotech company in just over a month to report success in the fight against lupus on Thursday, sending its shares more than 50 percent higher.
Immunomedics and Belgium's UCB, which bought rights to the U.S. firm's lupus medicine epratuzumab three years ago, said the drug's treatment advantage over placebo reached 24.9 percent after 12 weeks of therapy in a Phase IIb clinical trial.
The study analysed the drug's impact on a number of measures of disease activity.
The result comes five weeks after Human Genome Sciences reported its lupus drug Benlysta, which it has partnered with GlaxoSmithKline, succeeded in a late-stage Phase III trial, sending Human Genome shares soaring.
Benlysta was the first drug ever to succeed in Phase III trials against lupus.
Analysts at Jefferies said the headline data for UCB and Immunomedics' rival product was encouraging but, given the high failure rate of lupus drugs, they remained cautious. The brokerage is retaining its conservative $150 million peak sales and 30 percent likelihood of success until full details of the Phase IIb results are released.
Still, investors in Immunomedics jumped on the news, boosting the stock 57 percent to the highest level in more than five years.
Epratuzumab is an antibody-based drug that was licensed to UCB by Immunomedics for all autoimmune disease indications in 2006.
It is the most advanced product in UCB's immunology disease pipeline and is significant for the Belgian group as it increases its focus on biotech medicines. Shares in UCB were up 1 percent at 1443 GMT.
UCB and Immunomedics said in-depth analysis of the data was now ongoing in preparation for a final-phase Phase III programme.
There have been plenty of drug failures in the area in the past and epratuzumab could yet trip up in final Phase III testing.
Lupus is a complex disease that causes the immune system to attack the body's own tissue and organs, including the joints, kidneys, heart, lungs, brain, blood and skin. Symptoms include achy joints, fever, arthritis, kidney damage, chest pain and skin rash.
Other companies working on lupus include ZymoGenetics , which is developing a drug in combination with Merck KGaA.
The disease affects an estimated 1.5 million people in the United States and 5 million worldwide, according to the Lupus Foundation of America.
(Editing by Will Waterman and Erica Billingham) Keywords: UCB/
(ben.hirschler@thomsonreuters.com; Tel: +44 20 7542 5082; Reuters Messaging: ben.hirschler.reuters.com@reuters.net; www.twitter.com/reutersBenHir)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Immunomedics rallies on lupus drug study
Aug 27, 2009, 7:27 a.m. EST
http://www.marketwatch.com/story/immunomedics-rallies-on-lupus-drug-study-2009-08-27
IMMU - in @ €4.19
UCB, Immunomedics drug shows promise for lupus
27-Aug-09 04:04AM
http://us.rd.yahoo.com/finance/external/reuters/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh17040_2009-08-27_08-04-01_lr596069_newsml&rpc=44&type=marketsNews
IMMU - Immunomedics drug shows promise for lupus !
UPDATE 2-UCB, Immunomedics drug shows promise for lupus
Thu Aug 27, 2009 4:04am EDT
http://www.reuters.com/article/marketsNews/idINLR59606920090827?rpc=44
* Positive Phase IIb results for UCB, Immunomedics drug
* Treatment advantage of epratuzumab vs placebo 24.9 pct
* Analysts say result promising but drug still high risk
* UCB shares up 2.5 percent
(Adds analyst comments)
By Anne Jolis and Ben Hirschler
BRUSSELS/LONDON, Aug 27 (Reuters) - An experimental lupus medicine from Belgium's UCB (UCB.BR) and U.S. biotech company Immunomedics (IMMU.O) proved effective in mid-stage tests, marking a fresh advance in finding new drugs for the disease.
The treatment advantage of epratuzumab over placebo reached 24.9 percent after 12 weeks of therapy in a Phase IIb clinical trial involving 227 patients, the two companies said on Thursday.
The study analysed the drug's impact on a number of measures of disease activity.
The result comes just five weeks after Human Genome Sciences (HGSI.O) reported its lupus drug Benlysta, which it has partnered with GlaxoSmithKline (GSK.L), succeeded in a late-stage Phase III trial, sending Human Genome shares soaring.
Benlysta was the first drug ever to succeed in Phase III trials against lupus.
Analysts at Jefferies said the headline data for UCB and Immunomedics' rival product was encouraging but, given the high failure rate of lupus drugs, they remained cautious. The brokerage is retaining its conservative $150 million peak sales and 30 percent likelihood of success until full details of the Phase IIb results are released.
Epratuzumab is an antibody-based drug that was licensed to UCB by Immunomedics for all autoimmune disease indications in 2006.
It is the most advanced product in UCB's immunology disease pipeline and is significant for the Belgian group as it increases its focus on biotech medicines. Shares in UCB rose 2.5 percent in early trade on Thursday.
UCB and Immunomedics said in-depth analysis of the data was now ongoing in preparation for a final-phase Phase III programme.
IMMU - Immunomedics drug shows promise for lupus !
UPDATE 2-UCB, Immunomedics drug shows promise for lupus
Thu Aug 27, 2009 4:04am EDT
http://www.reuters.com/article/marketsNews/idINLR59606920090827?rpc=44
* Positive Phase IIb results for UCB, Immunomedics drug
* Treatment advantage of epratuzumab vs placebo 24.9 pct
* Analysts say result promising but drug still high risk
* UCB shares up 2.5 percent
(Adds analyst comments)
By Anne Jolis and Ben Hirschler
BRUSSELS/LONDON, Aug 27 (Reuters) - An experimental lupus medicine from Belgium's UCB (UCB.BR) and U.S. biotech company Immunomedics (IMMU.O) proved effective in mid-stage tests, marking a fresh advance in finding new drugs for the disease.
The treatment advantage of epratuzumab over placebo reached 24.9 percent after 12 weeks of therapy in a Phase IIb clinical trial involving 227 patients, the two companies said on Thursday.
The study analysed the drug's impact on a number of measures of disease activity.
The result comes just five weeks after Human Genome Sciences (HGSI.O) reported its lupus drug Benlysta, which it has partnered with GlaxoSmithKline (GSK.L), succeeded in a late-stage Phase III trial, sending Human Genome shares soaring.
Benlysta was the first drug ever to succeed in Phase III trials against lupus.
Analysts at Jefferies said the headline data for UCB and Immunomedics' rival product was encouraging but, given the high failure rate of lupus drugs, they remained cautious. The brokerage is retaining its conservative $150 million peak sales and 30 percent likelihood of success until full details of the Phase IIb results are released.
Epratuzumab is an antibody-based drug that was licensed to UCB by Immunomedics for all autoimmune disease indications in 2006.
It is the most advanced product in UCB's immunology disease pipeline and is significant for the Belgian group as it increases its focus on biotech medicines. Shares in UCB rose 2.5 percent in early trade on Thursday.
UCB and Immunomedics said in-depth analysis of the data was now ongoing in preparation for a final-phase Phase III programme.
NexMed Q2 Earnings Call Transcript
August 26, 2009
http://seekingalpha.com/article/158435-nexmed-q2-earnings-call-transcript?source=feed
Electric Hummer H3E by Raser Drives over 50 Miles on Batteries in Test Drive
Date : 08/26/2009 @ 8:00AM
Source : Business Wire
Stock : Raser Technologies, Inc. (RZ)
http://ih.advfn.com/p.php?pid=nmona&cb=1251296072&article=39201729&symbol=NY^RZ
Electric Hummer H3E by Raser Drives over 50 Miles on Batteries in Test Drive
Date : 08/26/2009 @ 8:00AM
Source : Business Wire
Stock : Raser Technologies, Inc. (RZ)
http://ih.advfn.com/p.php?pid=nmona&cb=1251296072&article=39201729&symbol=NY^RZ
Raser Technologies, Inc. (NYSE: RZ), an energy technology company, announced results from a recent test drive demonstrating over 50 miles of all-electric range by its electric Hummer H3E during a preliminary road test.
“I am very proud of our team and their work to reach this important milestone,” said Jim Spellman, Vice President of Business Development. “Battery range of this innovative vehicle was more than sufficient to exceed our performance target of 40 miles in all-electric mode. In fact the H3E drove over 50 miles using only approximately 60% of the battery pack. This initial test indicates that the vehicle should easily achieve over 100 miles per gallon in typical local daily driving. The positive results from this test indicate that we can downsize our battery pack, reducing cost and weight of the vehicle, and still achieve the 40 mile all-electric range needed for optimized typical driving.”
The course used for the test included a combination of city and highway driving with an average speed of 45 mph and with speeds up to 60 mph. The 40-mile electric-only range test is significant because a majority of Americans drive fewer than 40 miles a day. When driving beyond 40 miles, the vehicle’s range extender would automatically generate the electricity needed to drive up to 400 miles. The range extender consists of a small gas powered engine which kicks in only to re-charge the batteries.
“It’s important to note that Raser’s electric Hummer H3E can achieve similar results to the Chevy Volt,” added Mr. Spellman. “The main difference is that our electric powertrain can be used in larger vehicles, such as SUVs and trucks. In fact, if we were to employ the method we believe was used recently by GM to estimate city fuel economy for the Volt, the electric Hummer H3E could achieve more than 190 mpg in city driving using about 70% of the battery pack.”
“The Hummer performed beautifully with better than expected fuel economy and great acceleration,” said Kraig Higginson, Chairman, Raser Technologies. “Most importantly, it did all this with zero direct emissions running entirely on electricity.”
To view video documentation of this test-drive, click on this link http://www.rasertech.com/test-drive
Raser plans to conduct additional testing to demonstrate the vehicle’s estimated total range of up to 400 miles using the on-board range extender.
The electric Hummer H3E is a plug-in electric vehicle powered by Raser’s proprietary E-REV (extended range electric vehicle) powertrain. The new electric powertrain replaces the vehicle’s large gasoline engine with a powerful electric motor-drive system, Lithium Ion batteries and a small, efficient, gas/electric generator or “range extender. When driving less than 40 miles a day in a typical drive, the vehicle should actually use little or no gas with near zero emissions. The cost of electric fuel averages just about 60 cents per equivalent gallon or about one forth the cost of gasoline on average.
For more information on Raser’s electric Hummer H3, see http://rasertech.com/hummer
IMO 10...9...8 - last station before...
pre-market currently at $22.57
!! pre-market now $22.89 !!
...back to VG-chart
(sold - to early!! rrrrrrrrrrr)
Human Genome Sciences: A takeover target?
Washington Business Journal
by Jeff Clabaugh Staff Reporter
Tuesday, August 25, 2009, 12:52pm EDT
http://www.bizjournals.com/washington/stories/2009/08/24/daily33.html?surround=lfn
Market rumors and published reports suggesting Human Genome Sciences Inc. will be acquired sent its shares up as much as 16 percent Tuesday to a seven-year high.
Human Genome Sciences (NASDAQ: HGSI) stock was 45 cents a share in March. It is now above $19 per share, an increase of 819 percent. That gives the Rockville-based company a market capitalization of $3.2 billion.
Human Genome’s rally began in July, when the company reported a second large order for its anthrax drug from the U.S. government, and after it reported positive results for its experimental lupus drug, a disease that is considered difficult to treat. The company is developing that drug with U.K. drug giant GlaxoSmithKline.
The Wall Street Journal and others, citing analysts and traders, named GlaxoSmithKline as the company that may acquire Human Genome Sciences.
Demand for Human Genome stock has been so strong the company was able to increase the size of its planned secondary stock offering earlier this month, raising nearly $358 million.
Human Genome Sciences posted a second quarter net loss of $65.4 million, an improvement over the $80.1 million it lost in the same quarter a year ago. Revenue more than doubled from a year ago to $26.7 million, largely from sales of its anthrax drug to the government’s stockpile, and from drug development agreements with Glaxo and from Novartis, its partner in developing a hepatitis C treatment.
Human Genome stock was up $2.70 to $19.88 per share in afternoon trading.
Human Genome shares jump on Glaxo takeover chatter
By Bill Berkrot
25.08.2009 18:51
http://www.finanznachrichten.de/nachrichten-2009-08/14778338-human-genome-shares-jump-on-glaxo-takeover-chatter-020.htm
NEW YORK, Aug 25 (Reuters) - Human Genome Sciences Inc shares were up nearly 13 percent on Tuesday on renewed chatter that GlaxoSmithKline Plc was set to pay a healthy premium for the company to gain full control of the promising lupus drug Benlysta.
Human Genome shares soared in mid-July after it released late-stage clinical data showing a significant improvement of lupus symptoms in patients taking the drug that many industry observers had written off.
It has been several decades since a new lupus treatment was approved in a field littered with clinical failures. The complex disease causes the immune system to attack the body's own tissues and organs, including the joints, kidneys, skin, heart and lungs.
Analysts said reports of Glaxo's interest in buying the biotechnology company, possibly before data from a second Phase III trial confirms the previous results and drives up the asking price, was the catalyst for the Human Genome share movement.
'There's a rumor that Glaxo is going to buy them that first surfaced in a trade publication. They reported that the fresh gossip was Glaxo would pay $30 a share for Human Genome Sciences,' said ThinkEquity analyst Jason Kolbert.
That would be close to double Human Genome's closing price at the end of last week.
'Benlysta could be a very big drug, a multibillion-dollar drug,' said Kolbert, who raised his Human Genome 12-month price target to $26 early this month, when the stock was trading just above $14.
'Lupus is an unmet need and it's a benign drug, so you don't have a risk/reward problem.'
Thomas Weisel Partners analyst Ian Somaiya agreed that Glaxo is a solid contender to step in and buy the biotech company.
'Any acquisition should be in the mid- to high $20s if not close to $30,' Somaiya said.
'The market opportunity for Benlysta is multibillion dollars,' he said.
'At a minimum in the lupus segment, the drug has the ability to generate at least $2 billion in (annual) sales with no competition. That's a very unique market segment, and the market valuation of the company still doesn't reflect it,' Somaiya said.
Somaiya and other analysts believe Benlysta could eventually be used to treat a host of other diseases, significantly expanding its sales potential.
'A very simple analysis of the market opportunity for Benlysta starts off in lupus, with potential expansion into lupus nephritis, which is a larger patient population, and potentially into lymphoma, if not autoimmune diseases like multiple sclerosis and rheumatoid arthritis,' Somaiya said.
Human Genome will present full details of the first successful Phase III trial at an upcoming medical meeting with data from the second pivotal trial expected sometime in November.
Human Genome shares were up $2.20, or 12.8 percent at $19.38 in midday trading on Nasdaq.
(Reporting by Bill Berkrot; editing by Andre Grenon) Keywords: HUMANGENOME/
(bill.berkrot@thomsonreuters.com; +1 646 223-6030; Reuters Messaging: bill.berkrot.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Human Genome shares jump on Glaxo takeover chatter
By Bill Berkrot
25.08.2009 18:51
http://www.finanznachrichten.de/nachrichten-2009-08/14778338-human-genome-shares-jump-on-glaxo-takeover-chatter-020.htm
NEW YORK, Aug 25 (Reuters) - Human Genome Sciences Inc shares were up nearly 13 percent on Tuesday on renewed chatter that GlaxoSmithKline Plc was set to pay a healthy premium for the company to gain full control of the promising lupus drug Benlysta.
Human Genome shares soared in mid-July after it released late-stage clinical data showing a significant improvement of lupus symptoms in patients taking the drug that many industry observers had written off.
It has been several decades since a new lupus treatment was approved in a field littered with clinical failures. The complex disease causes the immune system to attack the body's own tissues and organs, including the joints, kidneys, skin, heart and lungs.
Analysts said reports of Glaxo's interest in buying the biotechnology company, possibly before data from a second Phase III trial confirms the previous results and drives up the asking price, was the catalyst for the Human Genome share movement.
'There's a rumor that Glaxo is going to buy them that first surfaced in a trade publication. They reported that the fresh gossip was Glaxo would pay $30 a share for Human Genome Sciences,' said ThinkEquity analyst Jason Kolbert.
That would be close to double Human Genome's closing price at the end of last week.
'Benlysta could be a very big drug, a multibillion-dollar drug,' said Kolbert, who raised his Human Genome 12-month price target to $26 early this month, when the stock was trading just above $14.
'Lupus is an unmet need and it's a benign drug, so you don't have a risk/reward problem.'
Thomas Weisel Partners analyst Ian Somaiya agreed that Glaxo is a solid contender to step in and buy the biotech company.
'Any acquisition should be in the mid- to high $20s if not close to $30,' Somaiya said.
'The market opportunity for Benlysta is multibillion dollars,' he said.
'At a minimum in the lupus segment, the drug has the ability to generate at least $2 billion in (annual) sales with no competition. That's a very unique market segment, and the market valuation of the company still doesn't reflect it,' Somaiya said.
Somaiya and other analysts believe Benlysta could eventually be used to treat a host of other diseases, significantly expanding its sales potential.
'A very simple analysis of the market opportunity for Benlysta starts off in lupus, with potential expansion into lupus nephritis, which is a larger patient population, and potentially into lymphoma, if not autoimmune diseases like multiple sclerosis and rheumatoid arthritis,' Somaiya said.
Human Genome will present full details of the first successful Phase III trial at an upcoming medical meeting with data from the second pivotal trial expected sometime in November.
Human Genome shares were up $2.20, or 12.8 percent at $19.38 in midday trading on Nasdaq.
(Reporting by Bill Berkrot; editing by Andre Grenon) Keywords: HUMANGENOME/
(bill.berkrot@thomsonreuters.com; +1 646 223-6030; Reuters Messaging: bill.berkrot.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
WPTE - PartyGaming in $15m World Poker Tour deal
By John O’Doherty
Published: August 25 2009 10:06
Last updated: August 25 2009 10:26
http://www.ft.com/cms/s/0/75e95776-914d-11de-879d-00144feabdc0.html?referrer_id=yahoofinance&ft_ref=yahoo1&segid=03058&nclick_check=1
PartyGaming to buy World Poker Tour for $12.3 mln
* On Tuesday August 25, 2009, 6:26 am EDT
http://finance.yahoo.com/news/PartyGaming-to-buy-World-rb-575120717.html?x=0&.v=2
(Reuters) - British online gaming group PartyGaming Plc (LSE:PRTY.L - News) said on Tuesday it agreed to buy U.S.-based branded gaming firm WPT Enterprises Inc (NasdaqGM:WPTE - News), known as World Poker Tour, for $12.3 million in cash.
PartyGaming said it would also pay a minimum of $3 million over the next three years to World Poker Tour's vendors on an ongoing revenue share related to the assets purchased.
The acquisition is expected to be completed in the fourth quarter of 2009, PartyGaming said in a statement.
In a late evening release on Monday, WPT had said it agreed to sell substantially all of its operating assets other than cash, investments and certain excluded assets to Peerless Media Ltd, a unit of ElectraWorks Ltd, which is owned by PartyGaming.
PartyGaming is WPT's largest customer, accounting for 30 percent of its revenue for the six months ended June 28, WPT said in a regulatory filing.
Last month, PartyGaming had said it was looking for further acquisitions following its purchase of bingo website operator Cashcade for an initial 71.9 million pounds ($118.8 million at that time).
Earlier this month, rival online gaming firm 888 (LSE:888.L - News) said it was close to making an acquisition and expected a deal to be completed soon.
PartyGaming shares were down 0.5 percent at 268.2 pence in volatile trade by 0848 GMT on the London Stock Exchange.
(Reporting by Kumar Alagappan in Bangalore; Editing by Gopakumar Warrier)
UNI @ Rodman & Renshaw Annual Global Investment Conference
11th Annual Healthcare Conference
September 9-11,2009 New York Palace Hotel - New York, NY
http://www.rodmanandrenshaw.com/conferences?id=30&link=presenters
2009-09-10 // Henry Salon (5th Floor)
04:30 PM Unilife Medical Solutions Limited (ASX: UNI AU)
Biotech Calendar: Key Dates and Events
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40609693
Posted by: langlui Date: Tuesday, August 18, 2009 9:18:05 AM
In reply to: langlui who wrote msg# 52156 Post # of 54515
Biotech Calendar: Key Dates and Events
08/18/09 - 09:00 AM EDT
http://www.thestreet.com/print/story/10579594.html
BOSTON, Mass. (TheStreet) --The dog days of August are here. Nothing of much importance is going on. It's hot and humid in Boston, and I'm getting ready for a much-needed vacation. The rest will come in handy because the biotech sector gets back to business in September.
To get you ready, I've put together a calendar of September biotech events. Enjoy.
Aug. 24
U.S. Food and Drug Administration's responds to Cell Therapeutics'(CTIC Quote) priority review request for pixantrone as a treatment for non-Hodgkin's lymphoma.
Sept. 1
The Oncologic Drug Advisory Committee of the Food and Drug Administration meets to review Genzyme's(GENZ Quote) Clolar and Vion Pharmaceuticals'(VION.OB Quote) Onrigin, both as a treatment for acute myeloid leukemia.
Sept. 2
The same FDA advisory committee meets to review Allos Therapeutics'(ALTH Quote) pralatrexate for peripheral T-cell lymphoma.
FDA approval decision date for Endo Pharmaceuticals'(ENDP Quote) Nebido, a long-acting testosterone replacement therapy.
Sept. 7
FDA approval decision date for Spectrum Pharmaceuticals'(SPPI Quote) Zevalin, a drug for non-Hodgkin's lymphoma.
Sept. 9-10
Robert W. Baird Small Cap Health Care Conference
Sept. 9-11
Thomas Weisel Partners Healthcare Conference (Boston) and the Rodman & Renshaw 11th Annual Healthcare Conference (New York City)
Sept. 11-15
American Society for Bone and Mineral Research (ASBMR)
Sept. 12-15
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Sept. 13-15
American College of Clinical Pharmacology (ACCP)
Sept. 14-15
Morgan Stanley Healthcare Unplugged Conference
Sept. 16
The 16th Annual NewsMakers in the Biotech Industry, sponsored by BioCentury.
The Arthritis Drugs Advisory Committee of the FDA will review Auxilium Pharmaceutical's(AUXL Quote) Xiaflex for advanced Dupuytren's disease, a condition in which the tendons of the hand that help move the fingers of the hand become thickened and scarred.
FDA approval decision date for Theravance's(THRX Quote) antibiotic Telavancin.
Sept. 20-24
European Cancer Organization and European Society for Medical Oncology Multidisciplinary Congress
Sept. 21-23
UBS Global Life Science Conference
Sept. 24
FDA approval decision date for Eurand Pharmaceuticals'(EURX Quote) Zenpep, a drug for pancreatic insufficiency.
FDA approval decision date for Allos Therapeutics' Pralatrexate for peripheral T-cell lymphoma.
Dendreon(DNDN Quote) analyst day
Sept. 27-Oct. 1
European Association for the Study of Diabetes (EASD)
Important clinical trials with potential data readouts in September:
Company: Osiris Therapeutics(OSIR Quote)
Drug/indication: Prochymal for graft-vs.-host disease
Company: Acadia Pharmaceuticals(ACAD Quote)
Drug/indication: pimavanserin for Parkinson's disease pychosis (PDP)
Company: Arena Pharmaceuticals(ARNA Quote)
Drug/indication: lorcaserin for obesity
Company: Chelsea Therapeutics(CHTP Quote)
Drug/indication: droxidopa for orthostatic hypotension
HGSI - Chart Update
(0815ax in [again] @ €11.91)
11-Aug-09 / Reiterated / Leerink Swann / Outperform / $16 ==> $30
http://www.finviz.com/quote.ashx?t=hgsi&ty=c&ta=0&p=d
...new 52wk-hi @ $0.70
HGSI shrs, options move on takeover talk
http://www.finanznachrichten.de/nachrichten-2009-08/14766201-stocks-news-us-human-genome-shrs-options-move-on-takeover-talk-020.htm
http://uk.reuters.com/article/idUKN2414731520090824
Stocks on the move
Real-time Equity news
U.S. stock market report
1121 ET 24Aug2009-Human Genome shares rise on takeover talk
------------------------------------------------------------------------------
Shares of Human Genome Sciences rose and its call option volume
increased as takeover speculation swirled around the biotech company. In
morning trade, Human Genome shares were up 4.86 percent to $17.25. The stock
earlier hit a 52-week high of $17.47. 'Some investors are buying Human Genome
calls on talk that GlaxoSmithKline might make a bid for the biotechnology
company,' said WhatsTrading.com option analyst Frederic Ruffy. Officials from
Human Genome Sciences were not immediately available for comment. A spokeswoman
for Glaxo declined to comment. In all, about 10,000 calls and 4,130 puts traded
in Human Genome. Traders showed an early interest in HGSI Sept $20 and Oct $19
calls, Ruffy said.
Reuters Messaging: doris.frankel.reuters.com@reuters.net
1052 ET 24Aug2009-Markets up on energy, financial stocks
XL - Chart Update
(0815ax in @ €2.65)